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models for drug permeation studies include species differences, 
ethical issues, and high cost of animal experiments (Holmes et 
al., 2010). Although animal-based tests reproduce the dynamic 
stimuli of the intestinal environment mediated by the systemic 
blood circulation, it is impossible to selectively distinguish and 
decouple all the variables involved in the passage of molecules 
through the intestinal barrier in human intestinal tissues (Cao et 
al., 2006). For these reasons, there is a growing interest to devel-
op advanced, human-relevant in vitro models, where key param-
eters such as intestinal permeability and tissue barrier properties 
can be easily controlled and monitored at low cost and reduced 
time. 
In vitro models of human intestinal epithelium are mostly 
based on the static culture of intestinal epithelial cell monolay-
ers derived from colon adenocarcinoma (e.g., Caco-2), which do 
1  Introduction
The intestinal epithelium is the main access point of nutrients and 
orally administered drugs to the systemic circulation (Ganapathy, 
2012). Molecules can pass through the intestinal barrier by two 
main parallel routes: the transcellular pathway, in which drugs are 
transported through the cell membrane, and the paracellular path-
way, in which drugs pass through the intercellular spaces (Gro-
schwitz and Hogan, 2009). Studies on the intestinal absorption of 
molecules that consider the relative importance of these two alter-
native routes of entry are often limited due to a lack of validated or 
widely accepted experimental models (Stewart et al., 1995). 
The use of animal models to evaluate gastrointestinal (GI) 
toxicity often fails to uncover the drug toxicities seen after hu-
man use. Concerns related to the currently available in vivo 
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Abstract
Intestinal permeability is crucial in regulating the bioavailability and, consequently, the biological effects of drugs and 
compounds. However, systematic and quantitative studies of the absorption of molecules are quite limited due to a lack 
of reliable experimental models able to mimic human in vivo responses. In this work, we present an in vitro perfused 
model of the small intestinal barrier using a 3D reconstructed intestinal epithelium integrated into a fluid-dynamic biore-
actor (MIVO®) resembling the physiological stimuli of the intestinal environment. This platform was investigated in both 
healthy and induced pathological conditions by monitoring the absorption of two non-metabolized sugars, lactulose and 
mannitol, frequently used as indicators of intestinal barrier dysfunctions. In healthy conditions, an in vivo-like plateau of the 
percentage of absorbed sugars was reached, where mannitol absorption was much greater than lactulose absorption. 
Moreover, a model of pathologically altered intestinal permeability was generated by depleting extracellular Ca2+, 
using a calcium-specific chelator. After calcium depletion, the pattern of sugar passage observed under pathological 
conditions was reversed only in dynamic conditions in the MIVO® chamber, due to the dynamic fluid flow beneath the 
membrane, but not in static conditions. Therefore, the combination of the MIVO® with the EpiIntestinal™ platform can rep-
resent a reliable in vitro model to study the passage of molecules across the healthy or pathological small intestinal barrier 
by discriminating the two main mechanisms of intestinal absorption.
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution and reproduction in any medium, provi-
ded the original work is appropriately cited. 
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MW: 342.296 g/mol) that moves through larger spaces between 
the cells (Bjarnason et al., 1995; Dastych et al., 2008; Sequeira 
et al., 2014) by passive diffusion. 
Perturbation or disruption of the intestinal barrier by com-
pounds or biomolecules can compromise intestinal barrier func-
tion and allow microbial entry, which can lead to patholog-
ic conditions including celiac disease (Collares-Buzato et al., 
1994), Crohn’s disease (Söderholm et al., 1999) and inflamma-
tory bowel disease (Halme et al., 2000). To investigate whether 
the model reflects changes in intestinal absorption under patho-
logical conditions and also barrier recovery, a model of altered 
intestinal permeability was generated via calcium chelation with 
EGTA (Collares-Buzato et al., 1994). The spontaneous ability of 
the intestinal epithelium to recover from this challenge was as-
sessed by quantifying the change of lactulose and mannitol pas-
sage through the intestinal barrier.
Reconstructed small intestinal tissues cultured under flow 
conditions may be more predictive of in vivo molecule absorp-
tion than current in vitro or animal models. Hence, our approach 
contributes to the development of a reliable alternative to animal 
use, in accordance with the 3R (Reduce, Refine, Replace) princi-
ples described by Russell and Burch (Russell et al., 1959). 
2  Materials and methods
Cell source 
Primary human cells of the small intestine were obtained as pre-
viously described (Ayehunie et al., 2018). Briefly, cells were ob-
tained from commercial sources or isolated from tissues obtained 
from the International Institute for the Advancement of Medicine 
(IIAM; Scranton, PA) through the Organ Procurement Organi-
zation (OPO). All tissue specimens were collected from brain-
dead donors with informed consent from the next of kin. Sam-
ples were protected from ischemic injury by flushing with ice-
cold University of Wisconsin storage solution immediately after 
vascular clamping and resection. Epithelial cells and fibroblasts 
were isolated from ileum, jejunum, or duodenum. Cells were ex-
panded and cryopreserved for future use. 
Reconstructed in vitro 3D tissue model of small  
intestine – EpiIntestinal™ 
The human small intestine cells were obtained and used to pro-
duce a reconstructed tissue model as described before (Ayehu-
nie et al., 2018). Briefly, cryopreserved intestinal epithelial cells 
were thawed and seeded onto collagen-coated cell culture inserts 
(MatTek Corporation, 0.6 cm2) in a proprietary medium formu-
lation (SMI-100-MM, IVLSL, Bratislava, Slovakia). Cells were 
cultivated in submerged conditions for 24 h, followed by cul-
tivation for 13 days at the air-liquid interface (ALI) at 37°C, 
5% CO2 and 98% relative humidity. During the ALI culture pe-
riod, these tissues (designated SMI-100 or EpiIntestinal™) were 
fed basolaterally through the membrane of the cell culture in-
serts of the 24-well plate. To keep the apical layer moist/hydrat-
ed, 100 µL of culture medium (MatTek Corporation) was ap-
plied topically every other day. To complete cellular differenti-
not reproduce the production of mucus or differentiate into vil-
li-like structures to recapitulate the physiology of the human in-
testine. Also, Caco-2 cultures form a non-physiological barrier 
due to paracellular junctions that are much tighter and less per-
meable than those of native human intestinal epithelium (Ayehu-
nie et al., 2018). The average tight junction pore radius of Ca-
co-2 cells is estimated to be 3.7 Å, compared to 8-13 Å typical 
of native human tissue (Tavelin et al., 2003). Moreover, transep-
ithelial electrical resistance (TEER) measurements for Caco-2 
monolayers/tissues range from 250 to 2400 Ω*cm2 compared to 
TEER values of 12-120 Ω*cm2 for human small intestinal tis-
sue (Gupta et al., 2013; Tavelin et al., 2003). Caco-2 cells also 
have other limitations such as: (i) weak or no expression of im-
portant intestinal metabolic enzymes such as cytochrome P450 
(CYP3A) (Le Ferrec et al., 2001), (ii) lack of the crypt-villus ax-
is, which is important for fluid and ion transport, and (iii) vari-
ability in cell line and clone selection, which can lead to 20-fold 
differences in TEER from laboratory to laboratory (Huang and 
Adams, 2003). Despite the recent efforts in establishing alterna-
tives to animal tests for intestinal absorption, there is still a lack 
of reliable models with physiological relevance (Marrella et al., 
2018).
Recently, 3D human intestinal cultures were developed to 
overcome these limitations. Such intestinal tissue models utilize 
primary human intestinal cells to produce a highly differentiated 
and polarized epithelial structure including the different cellular 
phenotypes such as enterocytes, MUC2+ (goblet) cells, Paneth 
cells, enteroendocrine cells, and tuft cells. This 3D EpiIntesti-
nal™ tissue model can be cultured over 6 weeks, which makes 
it ideal to run long term and repeat/chronic dosing experiments. 
The model is highly reproducible with lower lab-to-lab variation 
than for Caco-2 (Markus, et al., 2017). EpiIntestinal™ tissues 
have morphological and ultrastructural features such as villi-like 
structures and brush border formation that resembles normal 
human intestinal epithelium (Ayehunie et al., 2018). However, 
these 3D reconstructed tissues are usually static and therefore 
lack physiological fluidic stimuli of the living microenviron-
ment (Benam et al., 2015). 
Therefore, in this study, the EpiIntestinal™ tissue was inte-
grated into a fluidic bioreactor commercialized as MIVO® by 
React4life S.r.l. Genova, Italy. This novel in vitro platform com-
bines the advantages of 3D human small intestinal tissue and 
flow conditions that mimic the physiological microenvironment 
of the gut. The platform allows the quantitative biochemical 
analysis of permeability/metabolism of molecules (e.g., lactu-
lose and mannitol) over time as well as the morphological char-
acterization of the 3D tissue cultured in a sterile environment 
under either static or dynamic conditions. 
Two sugar molecules commonly used in the clinic to iden-
tify intestinal barrier disruption were used to characterize the 
model: Mannitol is a small molecule (molecular diameter of 6.5 
Å; MW: 182.172 g/mol) that is mainly transported through the 
pores on the villi surfaces (transcellularly), although it may also 
pass across the intestinal epithelium via paracellular transport, 
especially after tight junction disruption, due to its small size. In 
contrast, lactulose is a disaccharide (molecular diameter: 9.5 Å; 
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ation and stratification, cells were cultured for a total of 14 days 
prior to shipment and use to run the experiments within the bio-
reactor. Figure 1 shows the typical histology of the EpiIntesti-
nal™ (SMI-100) model.                            
MIVO fluidic chamber
In vitro diffusion studies were performed using a compartmental 
fluidic device (commercialized as MIVO® by React4life S.r.l., 
IT). The diffusion system designed and implemented in this 
study is shown schematically in Figure 2.
MIVO® is composed of a chamber made of transparent USP-
VI biopolymer and connected to a closed-loop fluidic circuit. The 
bioreactor fits commercially available 24-well trans-well inserts. 
Briefly, after 24 h of culture at ALI culture conditions to allow 
physiological (luminal) exposure conditions, 24-well EpiIntesti-
nal™ inserts were placed into and cultured within the bioreactor, 
forming two fluidically independent chambers: the donor cham-
ber, which was filled with 0.2 mL sugar solution (either lactulose 
or mannitol) at different concentrations, and the receiver cham-
ber, connected to the fluidic circuit and filled with 2.5 mL phos-
phate buffered saline (PBS). The fluidic circuit was connected 
by paraben-free transparent tubes to a peristaltic pump (Watson 
Marlow), and PBS was pumped through the lower chamber at a 
rate of 2.3 mL/min, simulating the capillary flow rate (0.1 cm/s). 
The PBS therefore flows in the basolateral chamber, beneath 
the membrane, in a closed-loop circuit, driven by the peristaltic 
pump (Fig. S1, S21).                       
Transepithelial electrical resistance (TEER) measurement 
To obtain baseline data on tissue barrier, TEER was measured 
prior to exposure of tissues to lactulose or mannitol. TEER mea-
surement was performed following the standard protocol pro-
vided by MatTek (Bratislava, Slovakia). Briefly, tissues were 
equilibrated with SMI-100-MM medium (MatTek) overnight 
prior to TEER measurement. Then tissues were transferred to 
TEER buffer (100mM KCl) and TEER measurement was per-
formed using an EVOM2 (World Precision Instruments, Saraso-
ta, FL, USA) apparatus. To minimize any effect of TEER buffer, 
tissues were transferred back to medium and left to recover at 
37°C for 25 min. 
Permeability of lactulose and mannitol
Intestinal barrier integrity was characterized by monitoring the 
absorption of the two non-metabolized sugars, lactulose and 
mannitol. Mannitol permeates through hydrophilic pores of the 
cell membrane (transcellular route) and lactulose is absorbed 
through the tight junctions (paracellular route). 
0.2 mL lactulose (Roche, Basel, Switzerland) was topically 
applied at 55.5 or 44.4 mg/mL for 30, 60, 90, 120, or 150 min. 
At the end of each exposure time, the circulating solution in the 
receiver chamber was collected and the quantity of lactulose per-
meated through the epithelium was assessed spectrophotomet-
rically by using a UV-3100PC UV/VIS scanning spectropho-
tometer (VWR International, Radnor, Pennsylvania, USA). Ab-
sorbance readings at 276 nm were used for quantification of the 
1  doi:10.14573/altex.1908311s
Fig.1: Typical histology of the EpiIntestinal™ (SMI-100) model 
(H&E staining) (A)
Immunohistochemistry showing MUC2+ mucus producing goblet 
cells (red) in intestinal tissues (white arrow). MUC-2 protein is  
a marker of mucous-producing goblet cells; DAPI positive nuclear 
staining is shown in blue (B). 
Fig. 2: Schematic representation of fluidic system  
and EpiIntestinal™ tissue used as interfacing tissue within  
the MIVO® fluidic chamber for absorption tests
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humidified incubator at 37 ±1°C, 5 ±1% CO2, 95 ±5% RH, a 
permeability test for lactulose and mannitol was carried out as 
described above. 
To assess the ability of the tissues to repair the damage induced 
by calcium depletion, the EpiIntestinal™ inserts were then incu-
bated for 24 h in SMI-100-MM maintenance medium at SCC. 
The tissues then again underwent permeability tests for lactulose 
and mannitol under static and dynamic conditions. 
Immunohistochemistry
To examine structural features, EpiIntestinal™ tissues were fixed 
in 4% paraformaldehyde solution at 4°C overnight, routinely 
processed, embedded in paraffin blocks, sectioned, and stained 
with hematoxylin and eosin. Immunohistochemical staining was 
performed on 5 μm paraffin sections mounted on glass slides, de-
paraffinized, and processed for antigen retrieval by heating in a 
citrate buffer (pH 7.4) for 45 min at 95-99°C. After 45 min, the 
specimens were removed from the heated water bath and left in 
the citrate buffer for an additional 20 min at RT. Rabbit polyclon-
al anti-villin (2 μg/mL, cat# ab97512, Abcam, Cambridge, MA) 
or anti-MUC2 antibody (2 μg/mL, cat# ab76774, Abcam, Cam-
bridge, MA) was applied for 60 min at RT and then visualized us-
ing secondary antibody (5 μg/mL, cat#A-11008, Goat anti-Rab-
bit IgG (H+L) Cross-adsorbed AlexFluor 488 ThermoFisher, 
Waltham, MA)). DAPI (cat#D1306, Life Technologies, Carls-
bad, CA) was used for nuclear staining. Images were captured 
using a FV1000 confocal microscope (Olympus America Inc., 
Center Valley, PA). 
amount of lactulose passed through the intestinal tissues (via in-
terpolation with a calibration curve). 
0.2 mL mannitol solution (Cat# 282631, Dufour, Italy) was ap-
plied at 105 or 210 mg/mL as described previously (Dastych et al., 
2008) for 30, 60, 90, 120, 150, 180, 210, or 240 min. At the end of 
each exposure time, the circulating solution in the receiver cham-
ber was collected and the quantity of mannitol permeated through 
the intestine tissue was measured by using the K-MANOL 
assay kit from Megazyme (Bray, Co, Wiklow, Ireland) according 
to the manufacturer’s instructions. 
Lactulose and mannitol permeability were expressed in terms 
of permeation percentage relative to the applied quantity and by 
calculation of the lactulose/mannitol ratios (LMR).
Model of the altered intestinal permeability via calcium  
depletion and its recovery
To alter the barrier properties of the EpiIntestinal™ model, 
extracellular Ca2+ was depleted by adding the calcium-specif-
ic chelator EGTA (ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid), also known as egtazic acid), which 
is known to progressively disassemble tight junctions, the cell-
to-cell adhesions essential to maintain epithelial barrier integri-
ty (Rothen-Rutishauser et al., 2002; Tsukita et al., 2001). Brief-
ly, SMI-100-MM maintenance medium supplied with the tis-
sues was supplemented with 25 mM EGTA (Sigma Aldrich, 
Saint Louis, MO, USA) and added both to the apical and ba-
solateral sides of EpiIntestinal™ tissues. After 45 min of incu-
bation at Standard Culture Conditions (SCC), i.e., in a sterile 
Fig. 3: Comparison of villin 
expression at the apical surfaces  
of intestinal tissues cultured  
under static (A) or dynamic (B) 
conditions in the MIVO® device 
Immunohistochemistry showing villin 
(green) expressing cells at the  
brush border (white arrows); DAPI 
positive nuclear staining is shown in 
blue.
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tured under dynamic conditions within MIVO®, compared to 
static cultured tissues (Fig. 3). 
Scanning electron microscopy (SEM) generated micrographs 
of intestinal tissue cultured in the MIVO® chamber under 
dynamic conditions (Panels A, B) or under static conditions 
(Panel C) also showed a well-developed brush-border in tissues 
grown under dynamic conditions, confirming the confocal vil-
lin staining pattern. The high magnification (Fig. 4B) confirms 
the good condition of the villi structure grown under dynamic 
conditions. 
3.2  Sugar permeability tests in healthy,  
dynamic conditions
The passage of lactulose and mannitol through the EpiIntesti-
nal™ tissue model cultured under dynamic conditions was an-
alyzed. The percentage of absorbed mannitol was much greater 
than that of lactulose at each time point (Figure 5) as expected. 
Moreover, a plateau was reached in both cases; lactulose reached 
steady state after 90 minutes, while mannitol reached steady state 
after 210 minutes. Figure S31 shows lactulose crystals deposited 
on the surface of the villi after the absorption test.
As shown in Figures 5, S4 and S51, the kinetics of lactulose ab-
sorption were similar at different concentrations, finally reaching 
a comparable amount of absorbed sugar (i.e., 49.61 ±3.95 mg/
mL for the highest concentration and 47.75 ±2.09 mg/mL for the 
lowest one), while the final values of mannitol absorbed were 
significantly different for the two concentrations, with a higher 
plateau value (about double) for the higher concentration. 
FE-SEM analysis
A field-emission scanning electron microscope (FE-SEM), part 
of a CrossBeam XB 1540 (Carl Zeiss, Oberkochen, Germany), 
with a resolution of 1.1 nm, was used for ultra-structural feature 
characterizations of the 3D tissue culture. To avoid charging, the 
sample was coated with a thin layer of chromium (a few nm), 
which does not alter the morphology of the tissue. An electron 
beam energy of 20 keV, which enhances the morphological 
contrast obtained with secondary electrons, and an aperture of 
30 µm, which generates a narrow beam current for optimum res-
olution at high magnification, were used for imaging with a posi-
tive biased Everhart-Thornley detector. 
Data analysis
All experiments were performed at least in triplicates (biological 
replicates). Results are expressed as the mean ±SEM (standard 
error of mean). Statistical significance between groups was as-
sessed by two-tailed Student’s t-test.
3  Results
3.1  Morphological and ultrastructural characterization 
of the tissue under static and dynamic conditions
Confocal imaging of stained cryo-sectioned tissues showed a 
more pronounced expression of villin, a microfilament-associ-
ated, actin-binding protein typical of brush-border microvilli 
(Bretscher and Weber, 1980), when intestinal tissues were cul-
Fig. 4: FE-SEM analysis of intestinal 
tissue cultured within the MIVO® 
chamber under dynamic (Panels A, 
B) and static (C) conditions 
Bar is 30 µm (A), 5 µm (B), 40 µm (C).
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4  Discussion
Intestinal epithelium has a well-organized cellular structure com-
posed of multiple cellular phenotypes. Absorptive enterocytes 
form a seamless barrier connected by tight junctions that interact 
with adjacent cells and with intracellular proteins connected to 
the cytoskeleton (Groschwitz and Hogan, 2009). 
Formation of a physiological barrier in most of the in vitro 
models of intestinal epithelia is detectable by trans-epitheli-
al electrical resistance (TEER) measurements (Srinivasan et al., 
2015). In general, this technique provides information about the 
state of barrier integrity of the intestinal tissue, which directly 
affects the paracellular passage of molecules, especially large 
ones like lactulose. However, it is difficult to monitor the passage 
of small molecules, like mannitol, which also can exploit other 
mechanisms (e.g. transcellular).
Here we describe an in vitro approach that allows measure-
ment of both paracellular and transcellular intestinal absorption 
by adapting sugar permeability tests commonly used in the clin-
ic. Modeling pathological conditions by means of calcium che-
lation allows comparison of the sugar translocation capacity be-
tween healthy, diseased, and recovered tissue from the apical to 
the basolateral surface. 
We show that the overall percentage of mannitol passed 
through the intestinal tissue is higher than that of lactulose, 
which is in agreement with historical and clinical data (Bijlsma 
et al., 1995; Ukabam and Cooper, 1984). This data is indicative 
of the relevance of the model for permeation studies. While para-
cellular absorption is strictly related to the integrity of the cellu-
lar tight junctions, transcellular absorption depends on the avail-
able cellular surface area, which is quite large in the model due to 
the presence of folds and villi-like structures.
It is noteworthy that the percentage of lactulose permeation in 
two hours reached the same plateau value starting from different 
3.3  Sugar permeability tests in pathological  
conditions
The sugar permeability tests were repeated after EGTA treatment 
to evaluate the effects of the progressive disassembly of tight 
junctions on the two absorption routes. No significant differenc-
es in mannitol absorption were observed between EGTA treated 
and control tissue (Fig. 6A), however, the amount of lactulose 
passed through the membrane was significantly higher after the 
EGTA treatment (p < 0.05) (Fig. 6B). Moreover, the LMR mea-
sure of the damaged tissues was higher (0.02) than that measured 
for healthy tissues, in line with clinical results that reported that 
values increase during the pathogenesis of many gastrointestinal 
diseases.
The TEER measurement revealed that barrier integrity of all 
the tissues was within specification with TEER values of ~100 
Ohm*cm2 before EGTA treatment. The addition of EGTA to me-
dium for 20 or 45 minutes resulted in a rapid decrease of barrier 
integrity, as demonstrated by the decrease of TEER by more than 
50% compared to untreated tissues (Fig. 7). 
3.4  Sugar permeability tests after tissue recovery
To evaluate the intestinal tissues’ ability to recover from EGTA 
treatment, tissue samples were incubated for 24 hours in com-
plete SMI-100 maintenance medium after EGTA treatment. 
Since EGTA treatment showed no significant difference for man-
nitol permeation/absorption, only lactulose permeability was as-
sessed in tissues after recovery from EGTA treatment under ei-
ther static or dynamic conditions. 
Interestingly, the pattern of lactulose passage was completely 
restored only in dynamic conditions (Fig. 6B). When the experi-
ment was carried out in static conditions (Fig. 6C), the EpiIntes-
tinal™ tissue failed to restore the normal barrier function, main-
taining a higher percentage of lactulose passage compared to the 
healthy tissue before the EGTA treatment. 
Fig. 5: Comparison of the absorption of two different concentrations of lactulose (A) and mannitol (B) by healthy intestinal  
tissue in dynamic conditions (MIVO® device) 
Values are presented as mean ±SEM. N = 6. Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
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open and seal the barrier in the event of injury, healing, and oth-
er signals (Shen, 2012; Chelakkot et al., 2018). Mannitol absorp-
tion, on the other hand, was much faster for the higher sugar con-
centration, in accordance with the Michaelis-Menten kinetic of a 
typical enzyme-catalyzed reaction as reported previously (Dialli-
nas and De Koning, 2014; Vivian and Polli, 2014). 
Although lactulose and mannitol mainly pass through different 
intestinal routes, several studies have shown that a small mole-
cule like mannitol can be transported also through the intercellu-
lar spaces (Kotzé et al., 1998). This occurs because the tight junc-
tions in the intestinal epithelium that regulate paracellular trans-
port are size-selective (Maiti, 2017). In fact, a non-metabolized 
probe penetrates the intestinal barrier with a rate proportional to 
its molecular size (Hollander, 1993). 
Therefore, the routes available for absorption of large mole-
cules (e.g. lactulose) are obviously fewer than those available 
for smaller molecules (e.g. mannitol). Accordingly, it is report-
ed that a higher amount of mannitol is generally absorbed (15%) 
compared to lactulose (0.1%) in normal patients (Ukabam and 
Cooper, 1984). In fact, there are historical data that indicate that 
mannitol can be absorbed via both intercellular spaces (Hol-
lander, 1992; Menard et al., 2012) and transcellular permeation 
mechanisms (Menzies, 1984; Musa et al., 2019; Paroni et al., 
2006) involving numerous small water pores situated in the cell 
membranes of the mucosal enterocytes.  However, to our knowl-
edge, there are no studies, prior to our work, on the in vitro intes-
tinal mechanisms of passage of mannitol and lactulose using 3D 
primary cell-based small intestinal tissues (commercially avail-
able and highly reproducible) in a fluid-dynamic environment 
resembling the physiological microenvironment of human intes-
tinal tissues.
Our results show that the absorption routes of the two sugars 
are different, in line with the clinical knowledge that routinely 
uses the LMR index calculated from urinary recovery to identify 
concentrations in terms of the absorbed absolute lactulose value. 
However, the levels of mannitol passed though the tissue were 
significantly different and proportional to the starting concentra-
tions in the donor chamber. A possible explanation could be that 
the human intestinal tissue adopts a controlled passive diffusion 
process aimed at keeping the amount of lactulose on the blood 
side constant. In fact, the paracellular passage is mediated by the 
tight junctions, which are able to dynamically regulate the pas-
sage of solutes and molecules. They are programmed to rapidly 
Fig. 6: Lactulose but not mannitol absorption increases in  
the absence of Ca2+ and is recovered after supplementation of 
Ca2+ only in dynamic culture conditions
(A) Absorption of mannitol in the absence and presence of EGTA  
in dynamic culture conditions (MIVO® chamber); (B) Absorption  
of lactulose in the absence and presence of EGTA and after 
recovery in EGTA-free medium in dynamic culture conditions 
(MIVO® chamber); (C) Absorption of lactulose in the absence and 
presence of EGTA and after recovery in EGTA-free medium in  
static culture conditions. 210 mg/mL mannitol; 44.4 mg/mL 
lactulose. Values are presented as mean ±SEM. N = 6. Student’s 
t-test. *P < 0.05; **P < 0.01.
Fig. 7: TEER measurement before and after EGTA treatment
Values are presented as mean ±SEM. N = 2. Student’s t-test.  
*P < 0.05; **P < 0.01.
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2-dimensional (2D) static cultures, can lead to an acidification 
of the pH in the tissue microenvironment, which can impair cell 
growth (Chen et al., 2010). 
Altered barrier permeability is the basis of pathogenesis of 
many gastroenterological and non-gastrointestinal pathologies 
such as infectious enterocolitis, chronic intestinal inflammatory 
diseases (IBD), irritable bowel syndrome (IBS), bacterial over-
growth syndrome of the small intestine (SIBO), celiac disease, 
and even atopic manifestations (Scaldaferri et al., 2012). Thus, in 
vitro modeling of a fluid-dynamic human intestine environment 
with disease-like perturbations offers an innovative and useful 
approach to the in vitro testing of potential therapeutic drugs on 
the recovery of the physiological function of the intestinal barri-
er (Tab. S11). 
In conclusion, the results reported in this study indicate that 
the MIVO® fluidic flow system combined with the EpiIntesti-
nal™ platform can be a valuable in vitro model of the healthy 
and pathological small intestinal barrier to study the passage of 
molecules by discriminating the two main intestinal absorption 
mechanisms. Moreover, this system could become a useful tool 
to test the effects of therapies and drugs on intestinal tissue bar-
rier function.
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